問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3348Cases

2013-05-28 - 2016-09-21

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects with Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    Blisibimod

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

黃春明
China Medical University Hospital

2013-07-01 - 2017-05-26

Phase II/III

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

  • Condition/Disease

    IgA Nephropathy

  • Test Drug

    Blisibimod

Participate Sites
6Sites

Terminated6Sites

2013-08-22 - 2015-06-30

Phase III

A randomized, double-blind, double-dummy, parallel group, international multicenter study assessing the efficacy and safety of a netupitant-palonosetron Fixed Dose Combination (FDC) compared to an extemporary combination of granisetron and aprepitant on the prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with cancer.

  • Condition/Disease

    nausea and vomiting

  • Test Drug

    netupitant-palonosetron Fixed Dose Combination (FDC)

Participate Sites
7Sites

Terminated7Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2021-03-17 - 2035-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2019-03-01 - 2020-06-30

Phase II

A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3

  • Condition/Disease

    Solid Tumors

  • Test Drug

    Debio 1347

Participate Sites
7Sites

Terminated7Sites

2019-01-01 - 2030-12-31

Phase III

ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

  • Condition/Disease

    Ovarian Cancer

  • Test Drug

    Rucaparib ; Nivolumab

Participate Sites
14Sites

Terminated14Sites

王鵬惠
Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2019-01-01 - 2028-12-31

Phase III

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP 1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed on or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma

  • Test Drug

    ASP-1929; Laser system PIT690.4-2500

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2019-06-01 - 2021-04-12

Phase III

An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension

  • Condition/Disease

    Central Neuropathic Pain

  • Test Drug

    DS-5565 (Mirogabalin)

Participate Sites
4Sites

Terminated4Sites

2014-07-01 - 2020-12-31

Phase III

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients

  • Condition/Disease

    Advanced Nasopharyngeal Carcinoma

  • Test Drug

    Epstein-Barr virus-specific autologous cytotoxic T lymphocytes

Participate Sites
8Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

謝清昀
China Medical University Hospital-Taipei

未分科

2015-08-01 - 2017-07-31

Phase III

A randomized, double-blind, placebo-controlled confirmatory study of the safety and efficacy of ASP015K in patients with rheumatoid arthritis (RA) who had an inadequate response to DMARDs

  • Condition/Disease

    rheumatoid arthritis (RA) who had an inadequate response to DMARDs

  • Test Drug

    ASP015K

Participate Sites
11Sites

Terminated10Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

蔡文展
Kaohsiung Municipal Gangshan Hospital

未分科

1 204 205 206 207 208 335
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB